In a significant advancement for Parkinson’s Disease (PD) therapy, researchers have developed a targeted nano formulation ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for ...

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...

d.umn.edu Parkinson’s disease (PD ... Some non-motor symptoms appear in late disease stages and are explained as the natural progression of PD pathology into other brain centres, including the frontal ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

Background Dementia is a common, debilitating feature of late Parkinson’s disease (PD). PD dementia (PDD) is associated with α-synuclein propagation, but coexistent Alzheimer’s disease (AD) pathology ...

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain. They found that a mutation in this protein promotes the secretion of a harmful ...

Parkinson's disease, the second most common type of progressive dementia after Alzheimer's disease, affects nearly 1 million people in the U.S. and an estimated 10 million individuals worldwide.

We demonstrate that recombinant alpha synuclein aggregates are toxic to primary cortical neuron cultures, are transferred between neurons, and induce Parkinson’s pSer129 pathology in mouse brains.

Parkinson’s disease (PD) is the second most common neurodegenerative ... Inoculation with extracts from PD patients’ brains induces the development and spread of α-synuclein pathology in rodents, ...